Korea Runs Three Reimbursement Speeds. September Shows All Three at Once.

Five separate Korean stories this week look like unrelated market news. Line them up against the calendar and they describe one system moving at three completely different speeds, all of them visible in the same month. If you are planning a Korean submission, the lane you are in matters more than the date you were approved.

The innovator lane runs in years, and approval is not the starting gun

Tecentriq’s adjuvant NSCLC indication was approved by the MFDS in November 2022. It reaches reimbursement in September 2026. Polivy’s R-CHP combination in previously untreated DLBCL was approved the same month, Roche Korea filed for first-line reimbursement in June 2023, and it lands in the same revision. Two products, one company, roughly forty-six months each.

What sat in between is instructive. HIRA’s Cancer Disease Review Committee set proposed criteria for adjuvant immunotherapy in July of last year, after five-year IMpower010 follow-up data became available. The Pharmaceutical Reimbursement Evaluation Committee gave a positive assessment in May. The public comment window is open now. Each of those steps is defensible on its own, and the aggregate is close to four years.

The evidence was not the constraint. IMpower010 showed a hazard ratio of 0.47 for disease-free survival at five years, with 65.1 percent of Tecentriq patients disease-free against 44.5 percent on best supportive care, and an identical 0.47 hazard ratio for overall survival. POLARIX showed a 27 percent reduction in progression or death against R-CHOP. What took the time was the sequence, not the data.

The generic lane runs in months, and it does not wait for the patent

Now look at what is happening in acid suppression. Korea’s P-CAB market grew from 100 billion won in 2021 to 368.5 billion won last year, and is expected to exceed 400 billion won this year. Takeda’s vonoprazan product Vocinti holds a compound patent to 2027.

Korean manufacturers are not waiting for it. Kyongbo Pharmaceutical and Mother’s Pharmaceutical have salt-modified versions ready, are negotiating reimbursement terms with the National Health Insurance Service, and are targeting listing as early as September. Seventy-two vonoprazan-based products from 38 companies already hold approval.

So in the same month that an oncology indication clears reimbursement forty-six months after approval, a modified version of an on-patent gastroenterology product may clear it before the originator’s patent has even expired. Those are the same agency, the same fiscal envelope and the same calendar.

The lesson for anyone planning a Korean launch is that the lane determines the timeline, and the lane is set long before the submission. An oncology indication with strong survival data still queues behind a committee sequence that runs in years, and the Korean filing plan should assume that queue rather than model from approval. A product entering a category where domestic manufacturers already compete moves at a completely different speed, because the pricing conversation is a known quantity and the volume is already forecastable. Build the Korean access plan around which of those two conversations you are having. If the answer is neither, because the product is a rare disease therapy with no comparator and no domestic equivalent, then plan for the possibility that the pricing conversation does not begin at all.

And there is a lane where the clock has not started

Elafibranor is approved in Korea as a second-line treatment for primary biliary cholangitis. Its price has not been set and national health insurance does not cover it. Patients who received it in the Korean clinical trial cannot continue on it now that the trial has closed.

Professor Kang Won-seok of Samsung Medical Center, who ran the Korean trial, described one patient whose alkaline phosphatase fell from triple digits into the normal range across a year of treatment, then began climbing again once the trial ended. That is the clearest possible illustration of what the gap costs: the drug worked, the patient responded, the response is being lost to a pricing process that has not concluded.

PBC has no domestic competitor product and no established Korean comparator, which is exactly the profile that produces no pricing anchor and therefore no easy negotiation. The same absence of comparators that HAS bodies elsewhere treat as an argument for premium pricing functions here as a reason the file does not move.

What to watch

Whether the September cancer criteria revision publishes with the PD-L1 threshold intact. The proposed criteria restrict Tecentriq to stage 2 to 3A with PD-L1 expression on at least 50 percent of tumour cells, which is narrower than the label and defines the funded population precisely.

Whether the vonoprazan salt-modified products actually list in September. If they do, that timeline becomes the reference point every Korean generic manufacturer plans against, and originators in that category should assume erosion begins before patent expiry rather than after.

And whether elafibranor gets a price at all this year. Rare disease pricing in Korea is where the system’s stated commitment to access meets its actual arithmetic, and a product that has been approved without a price is a clearer test than any policy statement.

None of these three speeds is irrational on its own. Cancer criteria need committee review, generic pricing is largely formulaic, and a rare disease with no comparator is genuinely hard to price. The problem is that a company planning a Korean portfolio has to model all three simultaneously, and nothing in the public process tells you in advance which lane a given product will end up in.